N
Niranjan Kanesa-thasan
Researcher at GlaxoSmithKline
Publications - 47
Citations - 2995
Niranjan Kanesa-thasan is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Dengue virus. The author has an hindex of 28, co-authored 46 publications receiving 2783 citations. Previous affiliations of Niranjan Kanesa-thasan include Novartis & Walter Reed Army Institute of Research.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers
Niranjan Kanesa-thasan,Wellington Sun,G. J. Kim-Ahn,S. Van Albert,Joseph R. Putnak,Alan D. King,B. Raengsakulsrach,H. Christ-Schmidt,K. Gilson,J.M. Zahradnik,D. W. Vaughn,Bruce L. Innis,Jean-François Saluzzo,Charles H. Hoke +13 more
TL;DR: The AvP live attenuated tetravalent d Dengue vaccine was most reactogenic, and preferential replication of dengue-3 virus may have affected its infectivity and immunogenicity.
Journal ArticleDOI
Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission.
Scott B. Halstead,Thomas G. Streit,Jack Guy Lafontant,Ravithat Putvatana,Kevin L. Russell,Wellington Sun,Niranjan Kanesa-thasan,Curtis G. Hayes,Douglas M. Watts +8 more
TL;DR: Dengue transmission rates were studied in school children in Carrefour Borough, Port-au-Prince, Haiti and observations, which are reminiscent of those in Africa, provide further evidence of a dengue resistance gene in black populations.
Journal ArticleDOI
A live, attenuated recombinant West Nile virus vaccine
Thomas P. Monath,Jian Liu,Niranjan Kanesa-thasan,Gwendolyn A. Myers,Richard Nichols,Alison Deary,Karen McCarthy,Casey Johnson,Thomas H. Ermak,Sunheang Shin,Juan Pablo Arroyo,Farshad Guirakhoo,Jeffrey S. Kennedy,Francis A. Ennis,Sharone Green,Philip Bedford +15 more
TL;DR: ChimeriVax-WN02 rapidly elicits strong immune responses after a single dose, and is a promising candidate warranting further evaluation for prevention of WN disease.
Journal ArticleDOI
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
Farshad Guirakhoo,Scott Kitchener,Dennis Morrison,Remi Forrat,Karen McCarthy,Richard A. Nichols,Sutee Yoksan,Xiaochu Duan,Thomas H. Ermak,Niranjan Kanesa-thasan,Philip Bedford,Jean Lang,Marie-Jose Quentin-Millet,Thomas P. Monath +13 more
TL;DR: Surprisingly, levels of neutralizing antibodies to DEN 1, 2, and 3 viruses in YF immune subjects persisted after 1 year, and can have practical implications toward development of a dengue vaccine.
Journal ArticleDOI
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine.
Robert R. Edelman,Steven S. Wasserman,Sacared A Bodison,Robert Putnak,Kenneth H. Eckels,Douglas B. Tang,Niranjan Kanesa-thasan,David W. Vaughn,Bruce L. Innis,Wellington Sun +9 more
TL;DR: Seven formulations met the serologic criteria required for an expanded trial, and three were sufficiently attenuated clinically to justify further testing and would be considered for an expand Phase II trial in the future.